Pulmonary fibrosis (PF) is a progressive, interstitial fibrotic lung disease characterized by persistent scar formation in the lung parenchyma and a reduced quality of life and poor prognosis for patients. The pathogenesis of PF is unknown and there is a lack of effective therapeutic agents, and animal models are the main tool to explore the pathogenesis of the disease and to find effective therapeutic agents. A variety of factors can induce fibrosis formation, and PF models can be induced to different degrees according to known etiology. Among them, bleomycin-induced models are widely used because of their reproducibility and similarity between fibrosis pathology and clinical conditions, and their induction methods mainly include intratracheal drip, intratracheal nebulization, tail vein injection, intraperitoneal injection and transnasal inhalation, and they are classified into single dose and multiple doses according to the frequency of induction. Based on the relevant literature, this paper summarizes the characteristics of the PF model established by BLM with different induction frequencies and induction methods, and provides a basis for the application of this model.